<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790513</url>
  </required_header>
  <id_info>
    <org_study_id>LIB003-011</org_study_id>
    <nct_id>NCT04790513</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients</brief_title>
  <acronym>LIBerate-H2H</acronym>
  <official_title>Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003, Evolocumab and Alirocumab in CVD Patients, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction (LIBerate-H2H)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIB Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LIB Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of LDL-C reductions at Week 12 of monthly (Q4W[≤ 31 days]) dosing of LIB003 300 mg&#xD;
      administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab&#xD;
      (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high&#xD;
      intensity statin and other LDL-C-lowering drug therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label Phase 3 study of 12 weeks duration comparing Q4W SC doses of&#xD;
      LIB003 300 mg, evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg. Approximately&#xD;
      220 males and females aged ≥18 years who fulfill all of the inclusion and exclusion criteria&#xD;
      will be enrolled at up to 25 sites in the United States. Patients will be stratified by&#xD;
      baseline LDL-C and randomized in a 2:2:1 ratio to LIB003 (88 patients), Repatha (88 patients)&#xD;
      or Praluent (44 patients) administered SC Q4W (≤31 days). The study will consist of a&#xD;
      Screening Period and a Treatment Period. The total study duration will be up to 21 weeks&#xD;
      which includes up to 9-week Screening Period (depending on period required for washout of&#xD;
      PCSK9 mAb and/or intensification of statin treatment) and 12 weeks of study drug treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, open-label with blinded lipid levels</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>lipid levels measured and central laboratory will be blinded to participants, investigators, and sponsor, DSMB and CEC (Cardiovascular Events Committee)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C reduction from baseline at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>LS Mean percent change from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieved ESC/EAS LDL-C goals</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of patients achieving ESC/EAS 2019 LDL-C target</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability and safety of each treatment: injection site reactions</measure>
    <time_frame>12 weeks</time_frame>
    <description>ISR (injection site reactions) after each dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg SC Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>evolocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>420 mg SC Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg SC Q4W</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lerodalcibep</intervention_name>
    <description>anti-PCSK9 small binding protein</description>
    <arm_group_label>LIB003 (lerodalcibep)</arm_group_label>
    <other_name>LIB003</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>evolocumab</intervention_name>
    <description>monoclonal antibody to PCSK9</description>
    <arm_group_label>evolocumab</arm_group_label>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>alirocumab</intervention_name>
    <description>monoclonal antibody to PCSK9</description>
    <arm_group_label>alirocumab</arm_group_label>
    <other_name>Praluent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  diagnosed with CVD or a high risk of CVD based on 2019 ESC/EAS guidelines&#xD;
&#xD;
          -  Weight of ≥40 kg (88 lb) and body mass index (BMI) ≥17 and ≤42 kg/m2&#xD;
&#xD;
          -  LDL-C ≥90 mg/dL and TG ≤400 mg/dL while on stable diet &amp; lipid-lowering oral drug&#xD;
             therapy (ie, high intensity statin with or without ezetimibe) and no PCSK9 mAb for 4&#xD;
             weeks if previously on Q2W dosing or 8 weeks if on Q4W dosing.&#xD;
&#xD;
          -  Females of childbearing potential must be using a highly effective form of birth&#xD;
             control if sexually active and have a negative urine pregnancy test at the last&#xD;
             Screening Visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  at screening visit: not on high intensity statin; mipomersen or lomitapide within 6&#xD;
             months; gemfibrozil within 6 weeks; bempedoic acid within 4 weeks; inclisiran within&#xD;
             12 months; apheresis within 8 weeks&#xD;
&#xD;
          -  HoFH defined clinically and/or genetically&#xD;
&#xD;
          -  History of prior or active clinical condition or acute and/or unstable systemic&#xD;
             disease compromising patient inclusion, at the discretion of the Investigator&#xD;
&#xD;
          -  estimated glomerular filtration rate &lt;30 mL/min/1.73m2 at screening&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction, history of liver transplant, and/or AST&#xD;
             or ALT &gt;2.5 × the ULN&#xD;
&#xD;
          -  Uncontrolled Type 1 or Type 2 diabetes mellitus, defined as fasting glucose ≥200 mg/dL&#xD;
             or glycated hemoglobin (HbA1c) of ≥9%&#xD;
&#xD;
          -  NY Heart Association class III-IV heart failure; or patients with last documented left&#xD;
             ventricular ejection fraction &lt;30%; planned PCI, CABG or cardiac surgery&#xD;
&#xD;
          -  Uncontrolled hypertension defined as evidenced by a reproducible (repeated 5 minutes&#xD;
             apart) sitting blood pressure ≥160 mmHg systolic or ≥100 mmHg diastolic;&#xD;
&#xD;
          -  Enrolled in another investigational device or drug study, or less than 30 days or 5&#xD;
             half-lives since ending another investigational device or drug study(ies), or&#xD;
             receiving PCSK9 or Lp(a) siRNA or locked nucleic acid-reducing agents within 12 months&#xD;
             of the Screening Visit;&#xD;
&#xD;
          -  Have any other finding which, in the opinion of the Investigator, would compromise the&#xD;
             patient's safety or participation in the study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan A Stein, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>LIB Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metabolic &amp; Atherosclerosis Research Center (MARC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lerodalcibep</keyword>
  <keyword>evolocumab</keyword>
  <keyword>alirocumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

